Associated tags: Coronary thrombosis, VTE, CE, Patient, Pulmonary embolism, FDA, Deep vein thrombosis, Medicine, Thrombosis, Pharmaceutical industry, Inari
Locations: IRVINE, CA, US, UNITED STATES, CALIFORNIA
Retrieved on:
Thursday, September 17, 2020
IRVINE, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the promotion of Drew Hykes to Chief Operating Officer, effective September 1, 2020.
Key Points:
- IRVINE, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the promotion of Drew Hykes to Chief Operating Officer, effective September 1, 2020.
- Mr. Hykes joined Inari as Chief Commercial Officer in September 2017.
- Drew has had a significant impact on our commercial success over the last three years, said Bill Hoffman, CEO of Inari Medical.
- "It's an honor to continue to help Inari Medical bring new technologies to many more physicians and their patients," said Hykes.
Retrieved on:
Thursday, August 27, 2020
IRVINE, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the management team is scheduled to speak at the following upcoming investor conferences.
Key Points:
- IRVINE, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the management team is scheduled to speak at the following upcoming investor conferences.
- Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.
- Inari is focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots.
- Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs.
IRVINE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2020.
Key Points:
- IRVINE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2020.
- Revenue was $25.4 million for the second quarter of 2020, compared to $27.0 million for the prior quarter and $10.1 million for the second quarter of 2019.
- Gross profit for the second quarter of 2020 was $21.9 million compared to $8.7 million for the second quarter of 2019.
- Inari Medical will host a conference call to discuss the second quarter financial results after market close on Tuesday, August 11, 2020 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
IRVINE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) today announced the company will be participating in the upcoming Canaccord Genuity 40th Annual Virtual Growth Conference.
Key Points:
- IRVINE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) today announced the company will be participating in the upcoming Canaccord Genuity 40th Annual Virtual Growth Conference.
- Inaris management is scheduled to present on Wednesday, August 12 at 4:30 p.m. Eastern Time.
- Interested parties may access a live and archived webcast of the presentation on the Investor Relations section of the companys website at: https://www.inarimedical.com/ .
- Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.
IRVINE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) today announced it will release financial results for the second quarter of 2020 after market close on Tuesday, August 11, 2020.
Key Points:
- IRVINE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) today announced it will release financial results for the second quarter of 2020 after market close on Tuesday, August 11, 2020.
- On the same day, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights.
- The live webinar of the call may be accessed by visiting the Events section of Inari's website at ir.inarimedical.com.
- Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.
The gross proceeds to Inari, before deducting underwriting discounts and commissions and offering expenses, were approximately $179.2 million.
Key Points:
- The gross proceeds to Inari, before deducting underwriting discounts and commissions and offering expenses, were approximately $179.2 million.
- Inaris common stock is listed on the Nasdaq Global Select Market under the symbol "NARI."
- BofA Securities and Morgan Stanley acted as joint lead bookrunning managers for the offering.
- Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.
IRVINE, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the pricing of its upsized initial public offering of 8,202,565 shares of its common stock at a public offering price of $19.00 per share, for total gross proceeds of approximately $156 million, before deducting underwriting discounts and commissions and offering expenses.
Key Points:
- IRVINE, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the pricing of its upsized initial public offering of 8,202,565 shares of its common stock at a public offering price of $19.00 per share, for total gross proceeds of approximately $156 million, before deducting underwriting discounts and commissions and offering expenses.
- In addition, Inari has granted the underwriters a 30-day option to purchase up to an additional 1,230,384 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
- The offering is expected to close on May 27, 2020, subject to the satisfaction of customary closing conditions.
- Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.
